Biological agents targeting interleukin-23/Th17 axis in inflammatory skin diseases: from basic research to clinical application
- VernacularTitle:靶向炎症性皮肤病中白细胞介素23/Th17轴的生物制剂——从基础到临床
- Author:
Ruixuan YOU
1
;
Zhuotong ZENG
;
Xiangning QIU
;
Rong XIAO
Author Information
- Keywords: Biological agents; Interleukin-17; Interleukin-23; Psoriasis; Dermatitis, atopic; Inflammatory skin diseases
- From: Chinese Journal of Dermatology 2023;56(11):1065-1069
- CountryChina
- Language:Chinese
- Abstract: Interleukin-17 (IL-17) has been proved to be closely associated with the pathogenesis of various inflammatory skin diseases. Its main source is Th17 cells, whose differentiation is evoked by interleukin-23 (IL-23). Therefore, the IL-23/Th17 axis is an emerging target for the treatment of inflammatory skin diseases. IL-17 antagonists, IL-23 antagonists and IL-12/23 antagonists have shown satisfactory efficacy and safety in the treatment of psoriasis, atopic dermatitis, hidradenitis suppurativa, pityriasis rubra pilaris and SAPHO syndrome in latest clinical trials. Accordingly, this review mainly summarizes progress in molecular signaling pathways in and pathophysiological basis of the IL-23/Th17 axis in the occurrence of inflammatory skin diseases, as well as clinical application of different biological agents targeting this axis.
